Paper · 42840941

UBA1 as a proteostasis-innate immunity checkpoint: lessons from vexas syndrome and therapeutic implications.

Zhang Y and 1 other. Front Immunol, 2026.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. UBA1 as a proteostasis-innate immunity checkpoint: lessons from vexas syndrome and therapeutic implications. Papers, record 42840941. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42840941

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: UBA1 as a proteostasis-innate immunity checkpoint: lessons from vexas syndrome and therapeutic implications.
Journal: Front Immunol
Year: 2026
Publication types: Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed: https://pubmed.ncbi.nlm.nih.gov/42840941/
DOI: https://doi.org/10.3389/fimmu.2026.1974344
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC13640003/
The journal: https://conductscience.org/library/journal-index/101560960
Revised in PubMed: 2026-10-27

Source PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	Kind	ORCID iD
1	Zhang Y	Yanyu
2	Su Q	Quanxin

Source PubMed

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Ubiquitin-Activating Enzymes	Major topic
Proteostasis	Major topic
Immunity, Innate	Major topic
Humans
Animals
Mutation
Myelodysplastic Syndromes
Skin Diseases, Genetic
Pyrazoles
Pyrimidines
Sulfonamides
Sulfides

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References62

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	40,787,890	American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel.	Arthritis Rheumatol	2026	https://conductscience.org/library/papers/40787890	PubMed
2	40,287,866	Emerging treatment approaches for VEXAS syndrome: a systematic review and meta-analysis.	Ann Hematol	2025	https://conductscience.org/library/papers/40287866	PubMed
3	17,597,759	Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging.	Nature	2007	https://conductscience.org/library/papers/17597759	PubMed
4	38,854,419	Targeting enhanced cell death represents a potential therapeutic strategy for VEXAS syndrome.	Rheumatol Adv Pract	2024	https://conductscience.org/library/papers/38854419	PubMed
5	34,213,531	Atypical splice-site mutations causing VEXAS syndrome.	Rheumatology (Oxford)	2021	https://conductscience.org/library/papers/34213531	PubMed
6	34,802,541	Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome.	Semin Hematol	2021	https://conductscience.org/library/papers/34802541	PubMed
7	41,068,485	Distinct characteristics of VEXAS-causative UBA1 M41 and recurrent functional non-M41 mutations.	Leukemia	2025	https://conductscience.org/library/papers/41068485	PubMed
8	34,805,767	Azacytidine Treatment for VEXAS Syndrome.	Hemasphere	2021	https://conductscience.org/library/papers/34805767	PubMed
9	22,116,877	The unfolded protein response: from stress pathway to homeostatic regulation.	Science	2011	https://conductscience.org/library/papers/22116877	PubMed
10	29,334,375	A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment.	Nat Med	2018	https://conductscience.org/library/papers/29334375	PubMed

1 to 10 of 62

See all 62 references

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first.

None in this release.

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42840941

GET https://conductscience.org/api/papers/v1/42840941/references?page=2

API reference For AI assistants